| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Over the last 12 months, insiders at Entera Bio Ltd. have bought $0 and sold $0 worth of Entera Bio Ltd. stock.
On average, over the past 5 years, insiders at Entera Bio Ltd. have bought $92,621 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 9,500 shares for transaction amount of $9,405 was made by Taitel Haya (director) on 2024‑01‑12.
| 2024-01-12 | Taitel Haya | director | 9,500 0.0311% | $0.99 | $9,405 | +66.06% | ||
| 2024-01-10 | Taitel Haya | director | 7,615 0.0264% | $0.77 | $5,864 | +126.22% | ||
| 2023-12-22 | LIEBERMAN GERALD M | director | 23,952 0.0901% | $0.71 | $17,006 | +174.62% | ||
| 2023-12-22 | Toledano Miranda Jayne | Chief Executive Officer | 23,952 0.0901% | $0.71 | $17,006 | +174.62% | ||
| 2023-08-22 | Taitel Haya | director | 18,000 0.0572% | $0.62 | $11,216 | +55.88% | ||
| 2023-08-21 | LIEBERMAN GERALD M | director | 20,000 0.0715% | $0.59 | $11,784 | +74.38% | ||
| 2023-08-21 | Ellis Sean | director | 40,000 0.1456% | $0.60 | $24,000 | +74.38% | ||
| 2023-04-04 | Toledano Miranda Jayne | Chief Executive Officer | 30,000 0.1073% | $1.01 | $30,300 | -18.78% | ||
| 2022-11-14 | LIEBERMAN GERALD M | director | 38,000 0.1348% | $0.57 | $21,740 | +44.46% | ||
| 2022-11-14 | Yaacov-Garbeli Dana | Chief Financial Officer | 26,580 0.0883% | $0.54 | $14,247 | +44.46% | ||
| 2022-11-11 | Ellis Sean | director | 30,000 0.1104% | $0.53 | $15,900 | +61.90% | ||
| 2022-11-11 | Toledano Miranda Jayne | Chief Executive Officer | 50,000 0.1846% | $0.53 | $26,585 | +61.90% | ||
| 2022-11-11 | Yaacov-Garbeli Dana | Chief Financial Officer | 30,000 0.1083% | $0.52 | $15,600 | +61.90% | ||
| 2022-07-21 | LIEBERMAN GERALD M | 19,491 0.0602% | $1.68 | $32,803 | -52.59% | |||
| 2022-07-21 | Ellis Sean | 14,900 0.0448% | $1.64 | $24,406 | -52.59% |
| LIEBERMAN GERALD M | director | 226961 0.495% | $474,348.49 | 4 | 0 | +60.22% |
| Toledano Miranda Jayne | Chief Executive Officer | 110752 0.2416% | $231,471.68 | 3 | 0 | +72.58% |
| Ellis Sean | director | 102100 0.2227% | $213,389.00 | 3 | 0 | +27.9% |
| Yaacov-Garbeli Dana | Chief Financial Officer | 56580 0.1234% | $118,252.20 | 2 | 0 | +53.18% |
| Taitel Haya | director | 35115 0.0766% | $73,390.35 | 3 | 0 | +82.72% |
$9,405,928 | 107 | 12.61% | $108.56M | |
$155,610,634 | 78 | -24.31% | $105.11M | |
$103,288,323 | 51 | 4.78% | $81.61M | |
$77,146,704 | 43 | 13.28% | $91.97M | |
$16,259,194 | 41 | 120.51% | $88.82M | |
$909,129 | 37 | 42.19% | $92.77M | |
$160,539,875 | 21 | -6.57% | $95.84M | |
$38,821,584 | 20 | -2.17% | $85.4M | |
$245,302 | 15 | -4.08% | $101.07M | |
Entera Bio Ltd. (ENTX) | $277,862 | 15 | 59.79% | $95.83M |
$15,799,576 | 12 | -39.52% | $97.72M | |
$145,194 | 11 | -27.37% | $93.61M | |
$135,589,307 | 10 | 32.46% | $99.71M | |
$68,692,148 | 6 | -39.10% | $102.66M | |
$20,729,984 | 5 | 51.71% | $83.52M | |
$105,079 | 4 | -41.57% | $91.62M | |
$73,632,168 | 3 | -63.24% | $108.43M | |
$16,554 | 2 | 41.65% | $96.87M | |
$10,096 | 1 | -13.07% | $84.46M |
| Increased Positions | 9 | +40.91% | 733,092 | +7.18% |
| Decreased Positions | 8 | -36.36% | 2M | -17.13% |
| New Positions | 4 | New | 638,171 | New |
| Sold Out Positions | <1 | Sold Out | 9,000 | Sold Out |
| Total Postitions | 23 | +4.55% | 9M | -9.95% |
| Knoll Capital Management, Llc | $12,705.00 | 12.79% | 5.88M | 0 | 0% | 2025-09-30 |
| Point72 Asset Management, L.P. | $2,545.00 | 2.56% | 1.18M | -2M | -56.31% | 2025-09-30 |
| Marshall Wace, Llp | $1,355.00 | 1.36% | 627,330 | +627,330 | New | 2025-09-30 |
| Schonfeld Strategic Advisors Llc | $1,225.00 | 1.23% | 566,956 | -37,566 | -6.21% | 2025-09-30 |
| Parkman Healthcare Partners Llc | $607.00 | 0.61% | 280,822 | -75,000 | -21.08% | 2025-09-30 |
| Northern Trust Corp | $321.00 | 0.32% | 148,668 | -52,077 | -25.94% | 2025-09-30 |
| Bessemer Group Inc | $304.00 | 0.31% | 140,843 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $191.00 | 0.19% | 88,400 | +24,100 | +37.48% | 2025-09-30 |
| Susquehanna International Group, Llp | $145.00 | 0.15% | 67,177 | +18,300 | +37.44% | 2025-09-30 |
| Signature Estate & Investment Advisors Llc | $102.00 | 0.1% | 47,328 | 0 | 0% | 2025-09-30 |